AVEO Oncology today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

MONDAY, May 21 (HealthDay News) -- Obese patients are more likely than other patients to have advanced, aggressive forms of papillary thyroid cancer when they're diagnosed with the disease, a new study has found. Thyroid cancer is on the rise in the United States and most of that increase ...

Covalon Technologies Ltd., an advanced medical technologies company, today announced it will be showcasing its advanced medical coating capabilities, including its SilverCoat Antimicrobial Silicone Foley Catheter as well as its recently FDA cleared IV Clear antimicrobial silicone adhesive film dressing from May 19th to May 23rd at the ...

By Amanda Gardner HealthDay Reporter WEDNESDAY, May 16 (HealthDay News) -- A drug approved to treat advanced prostate cancer appears to help men who have localized high-risk prostate cancer if given before surgery. Adding Zytiga (abiraterone) to conventional hormonal treatments eliminated ...

According to results of the PALETTE trial, treatment with pazopanib increased progression-free survival (PFS) almost three fold among patients with metastatic soft-tissue sarcoma whose disease had progressed following chemotherapy. The results are published Online First in The Lancet. In the United States, an estimated 11,000 individuals are diagnosed with soft-tissue ...

Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced ...

City of Hope researchers developed a combination therapy to treat late-stage type 1 diabetes that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study is published in the May 9 edition of Science Translational Medicine.

Infectious diseases - both old and new - continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with ...

Infectious diseasesboth old and newcontinue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author ...

(Arizona State University) Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed ...

The latest issue of the journal Annals of Oncology reports that a major new study by one of the country's leading cancer centers, the VU University Medical Center (VUMC) in Amsterdam has revealed that widespread use of advanced radiotherapy techniques in the Netherlands has resulted in improved survival rates amongst ...